Wanda Hu, MD
Ophthalmology · Sunnyvale, CANPI 1972803666
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,530 of the $10,729 with a category attached, or 60.9%. Aerie Pharmaceuticals, Inc. accounts for 79.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $9,631 and has fallen 98.0% since, to $194 in 2025.
Across 71 payments — averaging $151.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$9K
- AbbVie$763
- Amgen$439
- Carl Zeiss Meditec USA, Inc.$294
- Johnson & Johnson Surgical Vision, Inc.$148
- Bausch & Lomb, A Division Of Bausch Health US, LLC$142
- plus $384 from 8 others
Across 30 payments — averaging $1584.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$48K
What the payments were for
- Speaking & faculty fees$6,53061%
- Travel & lodging$1,53414%
- Food & beverage$2,29221%
- Education$801%
- Other$2943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 23 | $8,559 |
| AbbVie | 20 | $763 |
| Amgen | 3 | $439 |
| Carl Zeiss Meditec USA, Inc. | 1 | $294 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $148 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $142 |
| Sun Pharmaceutical Industries Inc. | 5 | $109 |
| Sight Sciences, Inc. | 4 | $88 |
| Alcon | 2 | $65 |
| Akorn, Inc. | 2 | $34 |
| Novartis | 2 | $34 |
| Shire North American Group Inc | 1 | $23 |
| Glaukos Corporation | 1 | $16 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$7,986
- Rhopressa$3,261
- PAVBLU$439
- CIRRUS 5000 with AngioPlex$294
- XEN GLAUCOMA TREATMENT SYSTEM$128
- XEN$125
- Tecnis Symfony IOL$107
- LOTEMAX$106
How this compares
$10,729 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 81 | $55,411 |
| LumiganBimatoprost | 85 | $46,862 |
| VyzultaLatanoprostene Bunod | 57 | $25,844 |
| RhopressaNetarsudil Mesylate | 54 | $25,398 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 61 | $18,692 |
| XiidraLifitegrast | 12 | $17,215 |
| Brinzolamide | 77 | $13,165 |
| Prednisolone Acetate | 294 | $12,982 |
| Latanoprost | 806 | $9,408 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 46 | $9,005 |
| Cyclosporine | 11 | $6,430 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,282 |
| Brimonidine Tartrate | 337 | $6,208 |
| Difluprednate | 49 | $5,727 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 334 | $5,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $8,559 | $80,809135 claims |
| AbbVieLumigan, Combigan | $763 | $53,144101 claims |
| AlconSimbrinza | $65 | $18,69261 claims |
| Thea Pharma Inc.Iyuzeh | $14 | $4,44815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Sunnyvale
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.